Quest Diagnostics Inc (DGX) stock
Close on Nov 13, 2026Market cap $28.56BP/E 25.9Yield –
Quest Diagnostics Inc grew revenue 9.1% to $11.84B over the twelve months to Sep 30, 2026. Operating income rose 12.5% to $1.72B, moving the operating margin from 14.1% to 14.6%. Free cash flow was $1.38B, down 1.3% from a year earlier. At the latest close the market valued the company at $28.56B, 25.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $28.56B
- P/E ratio
- 25.9
- Price to sales
- 2.41
- Price to book
- 3.74
- Dividend yield
- –
- Free cash flow yield
- 4.81%
Fundamentals
- Revenue
- $11.84B
- Net income
- $1.13B
- EPS, diluted
- $10.03
- Free cash flow
- $1.38B
- Book value per share
- $68.14
- Diluted shares
- 112M
Trading
- Next earnings
- Feb 9, 2027 (estimated, before the open)
- Previous close
- $259.65
- Open
- $260.17
- Day's range
- $258.56 – $260.90
- Volume
- 649,384
- Average volume (20 days)
- 968,228
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.32
- 52-week range
- $171.18 – $262.00
- RSI (14 days)
- 69.1
- Volatility (1 year)
- 23.9%
- Relative volume
- 0.64×
- WACC
- 7.3%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | DGX | S&P 500 | Difference | DGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.6% | -3.0% | +15.7 pts | ||
| 3 months | +10.4% | -2.8% | +13.2 pts | ||
| Year to date | +52.1% | +11.5% | +40.6 pts | ||
| 1 year | +40.7% | +13.5% | +27.3 pts | ||
| 3 years | +107.6% | +77.7% | +29.9 pts | +27.6% | +21.1% |
| 5 years | +90.6% | +72.6% | +18.0 pts | +13.8% | +11.5% |
| 10 years | +287.9% | +308.2% | −20.2 pts | +14.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Quest Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Update
- Results
About Quest Diagnostics
Services-Medical Laboratories
Quest Diagnostics provides diagnostic information services and clinical testing solutions derived from routine, non-routine, and specialized laboratory tests. Its operations comprise two primary segments: Diagnostic Information Services, which delivers clinical lab testing, esoteric diagnostics, and diagnostic insights, and Diagnostic Solutions, which includes risk assessment for insurers and healthcare information technology offerings. The company serves physicians across numerous medical specialties, hospitals and health systems, accountable care organizations, health plans, employers, government agencies, pharmaceutical firms, and individual consumers seeking direct testing options.
Company profile, executives and historyQuest Diagnostics stock: common questions
What is Quest Diagnostics's stock price?
DGX closed at $259.60 on Nov 13, 2026, down 0.02% on the day. Over the past 52 weeks it traded between $171.18 and $262.00.
What is Quest Diagnostics's market cap?
Quest Diagnostics was worth $28.56B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is DGX's P/E ratio?
DGX trades at 25.9 times earnings, based on diluted earnings per share of $10.03 over the twelve months to Sep 30, 2026.
How much revenue does Quest Diagnostics make?
Quest Diagnostics reported revenue of $11.84B for the twelve months to Sep 30, 2026, up 9.1% from a year earlier.
Does Quest Diagnostics pay a dividend?
No. Quest Diagnostics has not paid a cash dividend over the last twelve months.
When does Quest Diagnostics report earnings next?
Quest Diagnostics is expected to report Q4 FY2026 results on Feb 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DGX stock performed over the past year?
Including dividends, DGX returned +40.7% over the past year, against +13.5% for the S&P 500.
How many DGX shares are sold short?
4M shares were sold short at the latest FINRA report, 3.41% of the float, or 3.6 days of average trading volume.
Who are Quest Diagnostics's competitors?
Companies most similar to Quest Diagnostics by business, industry and size include LH, RDNT, NTRA, GH, FTRE.
See a number that looks wrong?